AI-generated summary
This is a consensus-style recommendation document on light therapy for seasonal affective disorder (SAD), summarizing prevalence, diagnosis, dosing, timing, side effects and eye-safety guidance. The authors report that light therapy is the first-line treatment for SAD, that side effects are rare and can be reduced by lowering the light dose, and that preliminary evidence exists for other conditions. The abstract does not describe the methods used to develop these recommendations.
- Who or what was studied
- Adults with seasonal affective disorder (about 2% of the adult population in Europe, with a female to male ratio of 4:1)
- Limits stated in the abstract
- The abstract does not state how the recommendations were derived, and evidence for uses beyond SAD is described only as preliminary.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on econtent.hogrefe.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Phototherapy, Lux, Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.